All other Oncology — Revenues:
Pfizer All other Oncology — Revenues: increased by 24.1% to $376.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.3%, from $377.00M to $376.00M. Over 4 years (FY 2021 to FY 2025), All other Oncology — Revenues: shows an upward trend with a 54.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful commercialization and market penetration of the company's secondary oncology pipeline, while a decrease may suggest market saturation or loss of competitive positioning in niche cancer therapies.
Detailed definition
This metric represents the total net sales generated by the company's secondary or emerging oncology product portfolio,...
Peer comparison
Peers typically report this as part of a broader 'Oncology' or 'Specialty Care' segment, often categorized under 'Other' or 'Emerging Products' to distinguish from core, high-revenue assets.
pfe_segment_all_other_oncology_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $60.00M | $53.00M | $83.00M | $81.00M | $82.00M | $80.00M | $1.60B | $467.00M | $455.00M | $399.00M | $0.00 | $301.00M | $347.00M | $268.00M | $285.00M | $377.00M | $380.00M | $272.00M | $303.00M | $376.00M |
| QoQ Change | — | -11.7% | +56.6% | -2.4% | +1.2% | -2.4% | >999% | -70.9% | -2.6% | -12.3% | -100.0% | — | +15.3% | -22.8% | +6.3% | +32.3% | +0.8% | -28.4% | +11.4% | +24.1% |
| YoY Change | — | — | — | — | +36.7% | +50.9% | >999% | +476.5% | +454.9% | +398.8% | -100.0% | -35.5% | -23.7% | -32.8% | — | +25.2% | +9.5% | +1.5% | +6.3% | -0.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's all other oncology — revenues:?
- Pfizer (PFE) reported all other oncology — revenues: of $376.00M in Q1 2026.
- How has Pfizer's all other oncology — revenues: changed year-over-year?
- Pfizer's all other oncology — revenues: decreased by 0.3% year-over-year, from $377.00M to $376.00M.
- What is the long-term trend for Pfizer's all other oncology — revenues:?
- Over 4 years (2021 to 2025), Pfizer's all other oncology — revenues: has grown at a 54.0% compound annual growth rate (CAGR), from $237.00M to $1.33B.
- What does all other oncology — revenues: mean?
- The total revenue generated by the company's secondary and emerging cancer treatment products.